The Future Is Now; #BioelectronicMedicine Med Tech That’s Changing Lives: (NASDAQ: $BSGM) (NASDAQ: $NVTR) (NYSE:
$BSX) (NASDAQ; $IRTC)
Point Roberts, WA,
Delta, BC - February 21, 2019 - Investorideas.com, a leading investor news resource covering
medical technology and healthcare stocks releases a snapshot looking at the
rapid advancements happening in the med tech sector and how many of these “far
off” projects are now on the verge of reality.
According to IDTechEx “The market for
bioelectronic medicine will exceed $60 billion by 2029.” They explain Bioelectronic medicine, or electroceuticals,
is the use of electrical stimulation to treat diseases of the human body in
ways that current pharmaceutical interventions cannot.
BioSig Technologies, Inc.
(NASDAQ: BSGM), a medical device
company developing a proprietary biomedical signal processing platform designed
to address an unmet technology need for the electrophysiology (EP) marketplace,
recently announced that the Company
successfully conducted the first patient cases using PURE EP™ System, its FDA
approved proprietary signal acquisition and processing technology. The first
commercial use of the System was completed at the Texas Cardiac Arrhythmia
Institute (“TCAI”) in Austin, TX.
Read this in full at https://www.investorideas.com/news/2019/biotech/02211Stocks-MedTech.asp
“With the use of the PURE EP™ System, I was
able to identify cardiac signals which were previously undetectable to me. I
believe that the PURE EP™ System could change diagnostic and treatment
strategies of arrhythmias, leading to more successful outcomes,” commented Dr.
Andrea Natale, who conducted the studies.
The PURE EP™ System
was used during standard studies on patients with persistent atrial
fibrillation and conducted in parallel with Abbott’s EnSite Precision™ and
Biosense Webster’s (Johnson & Johnson) CARTO™ cardiac mapping systems. The
goal of the first commercial use of the technology was aimed at validating the
System’s key value proposition elements and report on the overall user
experience during the procedure.
Kenneth L. Londoner,
Chairman and CEO of BioSig Technologies stated, “We are well positioned to
deliver on our strategic goals for 2019 and look forward to the expansion of
our evaluation efforts in the coming months.”
The BioSig
Technologies system will sell for $250,000 each, in addition to a $100,000
software license.
Nuvectra Corporation
(NASDAQ: NVTR), a medical device
company dedicated to neuromodulation, recently announced that the US Food and
Drug Administration (FDA) has advised that its review of the Company’s
pre-market approval (PMA) application for its Virtis Sacral Neuromodulation
(SNM) system has been extended beyond the expiration of the FDA’s 180-day
review period.
This small delay for
the company will most likely be overshadowed by the release of its financial
results for the fourth quarter and full year ended December 31, 2018 on
Thursday, February 28, 2019 after market close.
Boston Scientific Corporation (NYSE: BSX) has reported their results for Q4 and the full
year of 2018, in which they generated sales of $2.561 billion during Q4, representing growth of 6.3 percent on a
reported basis, 8.2 percent on an operational basis and 7.0 percent on an
organic basis, all compared to the prior year period.
For the full year
2018, the company generated sales of $9.823 billion, which represents growth of
8.6 percent on a reported basis, 8.0 percent on an operational basis and 7.2
percent on an organic basis, all compared to the prior year period.
Commenting on their
earnings, Chairman and CEO Mike Mahoney said, "Meaningful innovation and
focused execution helped us deliver strong financial results in 2018. We remain
driven by the opportunity to help more patients with our life-changing
technologies, including a robust long-term pipeline of new devices and
therapies."
iRhythm Technologies,
Inc. (NASDAQ: IRTC) technology combines wearable biosensor devices worn for up to 14 days
and cloud-based data analytics with powerful proprietary algorithms that
distill data from millions of heartbeats into clinically actionable
information. The company believes improvements in arrhythmia
detection and characterization have the potential to change clinical management
of patients.
Companies with
innovative products now being approved, tested, and brought to market are not
only showing great financial growth for their shareholders but are also
changing lives and adding new depths to the medical community. These
innovations in medical technology are showing us that the future of healthcare
is already here.
About Investorideas.com
Investorideas.com is a recognized news source
publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos
talking about cannabis,
crypto, technology including AI and IoT , mining ,sports biotech, water,
renewable energy and more . Investorideas.com original branded content includes
the daily Crypto
Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Social Media
Disclaimer/Disclosure:
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: this
news article featuring BioSig Technologies is a paid for service on
Investorideas.com (third party). Learn
more about costs and our services https://www.investorideas.com/News-Upload/
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment